Published in Am J Epidemiol on November 01, 1998
Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ (2012) 3.09
Behavioral intervention to promote smoking cessation and prevent weight gain: a systematic review and meta-analysis. Addiction (2009) 2.46
Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther (2011) 1.52
Estimating the effect of smoking cessation on weight gain: an instrumental variable approach. Health Serv Res (2006) 1.21
Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One (2013) 1.15
Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med (2010) 1.11
Associations between body mass index and substance use disorders differ by gender: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addict Behav (2008) 1.06
Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD (2011) 1.06
Cigarette smoking induces overexpression of a fat-depleting gene AZGP1 in the human. Chest (2009) 0.99
Smoking cessation and body weight: evidence from the Behavioral Risk Factor Surveillance Survey. Health Serv Res (2012) 0.92
Smoking cessation and the risk of diabetes mellitus and impaired fasting glucose: three-year outcomes after a quit attempt. PLoS One (2014) 0.92
An exploration of socioeconomic variation in lifestyle factors and adiposity in the Ontario Food Survey through structural equation modeling. Int J Behav Nutr Phys Act (2007) 0.91
The intestinal microbiota: its role in health and disease. Eur J Pediatr (2015) 0.88
Smoking cessation and subsequent weight change. Nicotine Tob Res (2014) 0.83
Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today (2015) 0.82
Nicotine alters food-cue reactivity via networks extending from the hypothalamus. Neuropsychopharmacology (2013) 0.81
Ten-year weight gain in smokers who quit, smokers who continued smoking and never smokers in the United States, NHANES 2003-2012. Int J Obes (Lond) (2015) 0.81
Weight Gain After Quitting: Attitudes, Beliefs and Counselling Strategies of Cessation Counsellors. J Smok Cessat (2008) 0.79
Dietary intake after smoking cessation among weight-concerned women smokers. Psychol Addict Behav (2012) 0.79
Effect of nicotine patch on energy intake and weight gain in postmenopausal women during smoking cessation. Eat Behav (2013) 0.78
The Relationship between Body Mass Index and Post-Cessation Weight Gain in the Year after Quitting Smoking: A Cross-Sectional Study. PLoS One (2016) 0.78
Trial design: blood pressure control and weight gain prevention in prehypertensive and hypertensive smokers: the treatment and prevention study. Contemp Clin Trials (2007) 0.78
Alterations in food group intakes and subsequent weight changes in adults: tehran lipid and glucose study. Int J Endocrinol Metab (2014) 0.77
Copd. BMJ Clin Evid (2011) 0.77
Leptin and smoking cessation: secondary analyses of a randomized controlled trial assessing physical activity as an aid for smoking cessation. BMC Public Health (2014) 0.76
Smokers' physical activity and weight gain one year after a successful versus unsuccessful quit attempt. Prev Med (2014) 0.76
The joint influence of gender and amount of smoking on weight gain one year after smoking cessation. Int J Environ Res Public Health (2014) 0.76
Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD. Nicotine Tob Res (2012) 0.76
Smoking and the risk of type 2 diabetes. Transl Res (2017) 0.75
Young woman smokers gain significantly more weight over 2-year follow-up than non-smokers. How Virginia doesn't slim. Appetite (2014) 0.75
Slimming World in Stop Smoking Services (SWISSS): study protocol for a randomized controlled trial. Trials (2013) 0.75
Smoking relapse and weight gain prevention program for postmenopausal weight-concerned women: A pilot study. Eat Behav (2015) 0.75
Copd. BMJ Clin Evid (2008) 0.75
Obesity and health-related decisions: An empirical model of the determinants of weight status across the transition from adolescence to young adulthood. Econ Hum Biol (2016) 0.75
Circulating leptin and pain perception among tobacco-dependent individuals. Biol Psychol (2015) 0.75
Comparative effectiveness of adding weight control simultaneously or sequentially to smoking cessation quitlines: study protocol of a randomized controlled trial. BMC Public Health (2016) 0.75
Invited commentary on "early and late weight gain following smoking cessation in the Lung Health Study". Am J Epidemiol (1998) 0.75
The short- and long-run effects of smoking cessation on alcohol consumption. Int J Health Econ Manag (2017) 0.75
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother (1983) 8.82
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med (1995) 7.52
IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A (2001) 6.91
Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet (1989) 6.58
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab (1982) 5.60
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med (2001) 4.48
Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry (2000) 4.35
Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet (1994) 4.28
Association between bovine digital dermatitis treponemes and a range of 'non-healing' bovine hoof disorders. Vet Rec (2011) 4.22
Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis (1992) 4.19
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell (1997) 4.18
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Functional anatomy of a common semantic system for words and pictures. Nature (1996) 4.14
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother (1980) 4.07
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet (2001) 3.96
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med (2000) 3.43
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. Am J Public Health (1993) 3.38
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
Testing hypotheses on specific environmental causal effects on behavior. Psychol Bull (2001) 3.31
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ (1996) 3.00
Mupirocin resistance. Lancet (1991) 2.88
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. Eur Respir J (2006) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun (1995) 2.80
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT). Laryngoscope (1996) 2.78
The one-year surgical outcome after prism adaptation for the management of acquired esotropia. Ophthalmology (1996) 2.76
DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity (2000) 2.75
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 2.69
Impaired development of Th2 cells in IL-13-deficient mice. Immunity (1998) 2.68
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.64
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
The health effects of swimming in ocean water contaminated by storm drain runoff. Epidemiology (1999) 2.58
Reward circuitry activation by noxious thermal stimuli. Neuron (2001) 2.56
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
MRI in schistosomiasis of conus medullaris and lumbar spinal cord. Lancet (1993) 2.40
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax (2006) 2.38
Mycobacterium chelonei isolation from broncho-alveolar lavage fluid and its practical implications. J Hosp Infect (1990) 2.37
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity (1997) 2.33
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Interleukin-17. Int Rev Immunol (1998) 2.31
Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry (2009) 2.29
Bronchodilator response in the lung health study over 11 yrs. Eur Respir J (2005) 2.26
Schizophrenia and Afro-Caribbeans. A case-control study. Br J Psychiatry (1991) 2.23
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Psychosis with good prognosis in Afro-Caribbean people now living in the United Kingdom. BMJ (1995) 2.22
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
A Jamaican psychiatrist evaluates diagnoses at a London psychiatric hospital. Br J Psychiatry (1999) 2.18
Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health (1995) 2.16
The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother (1984) 2.15
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med (2001) 2.03
Psychopathological syndromes and familial morbid risk of psychosis. Br J Psychiatry (1997) 2.02
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Associations of IL6 polymorphisms with lung function decline and COPD. Thorax (2009) 2.00
A computer-based record and clinical monitoring system for ambulatory care. Am J Public Health (1977) 1.99
Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis (1991) 1.99
Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J (1977) 1.97
Reproducibility of random amplified polymorphic DNA (RAPD) analysis among laboratories. PCR Methods Appl (1993) 1.97
Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy (1974) 1.97
Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann Neurol (1987) 1.96
Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med (1996) 1.96
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry (2002) 1.94
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Rapid diagnosis of Campylobacter pyloridis gastritis. Lancet (1986) 1.92
The cortical localization of the lexicons. Positron emission tomography evidence. Brain (1992) 1.91
A study of the test-retest reliability of ten olfactory tests. Chem Senses (1995) 1.88
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys (1986) 1.87
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol (1995) 1.86
Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. Chest (1993) 1.85